Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of the medicine Mevrometostat for treating RelapsedRefractory Small Cell Lung Cancer SCLC, Castration Resistant Prostate Cancer CRPC, and Follicular Lymphoma FL. This Phase 1 open-label study includes three parts, with Parts 1 and 2 closed for enrollment. Part 3, currently open, focuses on men with CRPC who have progressed after prior treatment. The study aims to understand how the study medicine behaves in the body and its impact on cancer. Participants in Part 3 receive Mevrometostat andor Enzalutamide. The study has two substudies a Bioequivalence BE substudy comparing two formulations of Mevrometostat, and a Drug-Drug Interaction DDI substudy with two cohorts. The BE substudy involves three single doses of Mevrometostat. The DDI substudy Cohort 1 takes Mevrometostat andor Itraconazole, and Cohort 2 combines Mevrometostat, Enzalutamide, and Itraconazole. After assessment phases, participants enter maintenance, taking Mevrometostat twice daily and Enzalutamide once daily until disease progression. Participants will visit the study center for dosing and monitoring, including evaluations of side effects, blood tests, and disease progression. The study measures dose-limiting toxicities, overall safety, and preliminary effectiveness using disease-specific criteria. Pharmacokinetics and patient-reported outcomes are also assessed at specific times. The study lasts approximately two years after the first participants visit, aiming to provide detailed safety and efficacy information.
Actively Recruiting
Researchers are evaluating the impact of real-time audio-video telemedicine consultations with a neonatologist, called teleneonatology, on early health outcomes of at-risk newborns delivered in community hospitals. This study uses a stepped wedge cluster randomized design to compare early mortality, morbidity, and delivery room care between neonates receiving teleneonatology support and those receiving usual care. The trial is led by Mayo Clinic and focuses on newborns facing significant resuscitation needs shortly after birth. The study involves two groups one where at-risk neonates receive care from the community hospital team with telemedicine support from a neonatologist located at a regional neonatal intensive care unit, and a control group where neonates receive the hospitals usual care without telemedicine consultation. The telemedicine connection allows real-time, two-way audio and video communication during advanced neonatal resuscitations. The study includes neonates born preterm under 32 weeks or requiring advanced resuscitation interventions such as prolonged positive pressure ventilation, alternative airway placement, or chest compressions. Participants include clinicians attending newborn resuscitations and eligible neonates born at participating community hospitals. Researchers will monitor outcomes including mortality within 7 days, early neonatal morbidity, combined mortality and morbidity, and the highest level of resuscitation given in the delivery room within the first hour. The study tracks these outcomes to assess the effect of teleneonatology on newborn health during this critical early period. The total study duration extends through May 2029.